Urgent hybrid approach in treatment of the acute myocardial infarction complicated by the ventricular septal rupture

Introduction. Ventricular septal rupture (VSR) in the acute myocardial infarction (AMI) is a rare but very serious complication, still associated with high mortality, despite significant improvements in pharmacological and surgical treatment. Therefore, hybrid approaches are introduced as new therapeutical options. Case Outline. We present an urgent hybrid approach, consisting of the initial percutaneous coronary intervention (PCI) of the infarct-related artery, followed by immediate surgical closure of the ventricular septal rupture, for treatment of high risk, hemodynamically unstable female patient with AMI caused by one-vessel disease and complicated by VSR and cardiogenic shock. Since the operative risk was also very high (EUROSCORE II 37%), this therapeutic decision was based on the assumption that preoperative PCI could promptly establish blood flow and thereby lessen the risks, duration and complexity of urgent cardiosurgical intervention, performed on the same day. This approach proved to be successful and the patient was discharged from the hospital on the fifteenth postoperative day in stable condition. Conclusion. In selected cases, with high operative risk and unstable hemodynamic state due to AMI complicated by VSR, urgent hybrid approach consisting of the initial PCI followed by surgical closure of VSR may represent an acceptable treatment option and contribute to the treatment of this complex group of patients

Antiproliferative and antimigratory effects of 3-(4-substituted benzyl)-5-isopropyl-5-phenylhydantoin derivatives in human breast cancer cells

In this study, a series of synthesized 3-(4-substituted benzyl)-5-isopropyl-5-phenylhydantoin derivatives as a potential antiproliferative and antimigratory agents were investigated. The possible antitumor mechanisms of investigated hydantoin derivatives were examined on human breast cancer cell line MDA-MB-231. The cells were treated with different concentrations of compounds (from 0.01 mu M to 100 mu M) during 24 h and 72 h. The proliferation index, nitric oxide production, apoptosis rate, and migration capacity were measured. The cell invasion potential was examined by measuring the level of MMP-9 and COX-2 gene expression. All tested compounds expressed antiproliferative activity and induced dose- and time-dependent increase in the level of nitrites. The investigated molecules significantly decreased cell survival rate, migration capacity and the expression levels of genes included in the process of tumor invasion. Obtained data suggest that the tested hydantoin derivatives express considerable antitumor activity by reducing cell division rate, elevating apoptosis level, and inhibiting the motility and invasiveness of breast cancer cells. The results obtained in this study indicate that investigated compounds express potential as a novel chemotherapeutic agents against breast cancer growth and progression. (C) 2020 The Author(s). Published by Elsevier B.V. on behalf of King Saud University

Evaluation of antioxidative effects of twelve 3-substituted-5,5-diphenylhydantoins on human colon cancer cell line HCT-116

Antioxidant effects of twelve 3-substituted-5,5-diphenylhydantoins in concentrations of 0.01, 0.1, 1, 10, and 100 μM on human colon cancer cell line HCT-116 were determined 24 h after treatment. The concentrations of superoxide anion radical (O2.-), nitrites (NO2-), and total glutathione were determined spectrophotometrically. Results indicated that treatment with all compounds induced a decrease in O2.- and an increase in NO2- concentrations in HCT-116 cells. Treatment with all compounds resulted in an increase in glutathione, and this indicates changes in redox homeostasis. Based on the obtained results, the investigated hydantoins act as antioxidants because they decrease the production of superoxide anion radical and increase concentrations of glutathione, but they also induce an increase in nitrite production. © TÜBİTAK

Evaluation of antioxidative effects of twelve 3-substituted-5,5-diphenylhydantoins on human colon cancer cell line HCT-116

Antioxidant effects of twelve 3-substituted-5,5-diphenylhydantoins in concentrations of 0.01, 0.1, 1, 10, and 100 mu M on human colon cancer cell line HCT-116 were determined 24 h after treatment. The concentrations of superoxide anion radical (O(2)radical anion), nitrites (NO2-), and total glutathione were determined spectrophotometrically. Results indicated that treatment with all compounds induced a decrease in O(2)radical anion and an increase in NO(2)(-)concentrations in HCT-116 cells. Treatment with all compounds resulted in an increase in glutathione, and this indicates changes in redox homeostasis. Based on the obtained results, the investigated hydantoins act as antioxidants because they decrease the production of superoxide anion radical and increase concentrations of glutathione, but they also induce an increase in nitrite production

Evaluation of antioxidative effects of twelve 3-substituted-5,5-diphenylhydantoins on human colon cancer cell line HCT-116

Antioxidant effects of twelve 3-substituted-5,5-diphenylhydantoins in concentrations of 0.01, 0.1, 1, 10, and 100 mu M on human colon cancer cell line HCT-116 were determined 24 h after treatment. The concentrations of superoxide anion radical (O(2)radical anion), nitrites (NO2-), and total glutathione were determined spectrophotometrically. Results indicated that treatment with all compounds induced a decrease in O(2)radical anion and an increase in NO(2)(-)concentrations in HCT-116 cells. Treatment with all compounds resulted in an increase in glutathione, and this indicates changes in redox homeostasis. Based on the obtained results, the investigated hydantoins act as antioxidants because they decrease the production of superoxide anion radical and increase concentrations of glutathione, but they also induce an increase in nitrite production

Structure-activity relationships of 3-substituted-5,5- diphenylhydantoins as potential antiproliferative and antimicrobial agents

A series of twelve 3-substituted-5,5-diphenylhydantoins was synthesized, including some whose anticonvulsant activities have already been reported in the literature. Their antiproliferative activities against HCT-116 human colon carcinoma cells were evaluated to determine structure-activity relationships. Almost all of the compounds exhibited statistically significant antiproliferative effects at a concentration of 100 μM, while the derivative bearing a benzyl group was active even at lower concentrations. Moreover, their in vitro antibacterial activities against Escherichia coli ATCC 25922, Staphylococcus aureus ATCC 25923 and clinical isolates of Escherichia coli, Proteus mirabilis, Pseudomonas aeruginosa, Enterococcus faecalis and Staphylococcus aureus were evaluated. Only the 3-iso-propyl and 3-benzyl derivatives showed weak antibacterial activities against the Gram-positive bacterium E. faecalis and the Gram-negative bacteria E. coli ATCC 25922 and E. coli

Uticaj strukture na antiproliferativnu i antibakterijsku aktivnost 3-supstituisanih-5,5-difenilhidantoina

A series of twelve 3-substituted-5,5-diphenylhydantoins was synthesized, including some whose anticonvulsant activities have already been reported in the literature. Their antiproliferative activities against HCT-116 human colon carcinoma cells were evaluated to determine structure-activity relationships. Almost all of the compounds exhibited statistically significant antiproliferative effects at a concentration of 100 μM, while the derivative bearing a benzyl group was active even at lower concentrations. Moreover, their in vitro antibacterial activities against Escherichia coli ATCC 25922, Staphylococcus aureus ATCC 25923 and clinical isolates of Escherichia coli, Proteus mirabilis, Pseudomonas aeruginosa, Enterococcus faecalis and Staphylococcus aureus were evaluated. Only the 3-isopropyl and 3-benzyl derivatives showed weak antibacterial activities against the Gram-positive bacterium E. faecalis and the Gram-negative bacteria E. coli ATCC 25922 and E. coli.Sintetisana je serija od dvanaest 3-supstituisanih-5,5-difenilhidantoina, koja obuhvata neke od derivata čije su antikonvulzivne aktivnosti poznate u literaturi. Određena je njihova antiproliferativna aktivnost prema ćelijskoj liniji humanog karcinoma kolona, kako bi se utvrdio uticaj strukture na aktivnost. Skoro sva jedinjenja ispoljavaju antiproliferativan efekat u koncentraciji od 100 μM, dok je derivat sa benzil grupom aktivan i u nižim koncentracijama. Dodatno je određena i antibakterijska aktivnost proučavanih jedinjenja prema Escherichia coli ATCC 25922, Staphylococcus aureus ATCC 25923 i kliničkim izolatima Escherichia coli, Proteus mirabilis, Pseudomonas aeruginosa, Enterococcus faecalis i Staphylococcus aureus. 3-Izopropil i 3-benzil derivati pokazuju slabu aktivnost prema gram-pozitivnoj bakteriji E. faecalis i gram-negativnim bakterijama E. coli ATCC 25922 i E. coli

Image1_Differences in left ventricular myocardial function and infarct size in female patients with ST elevation myocardial infarction and spontaneous coronary artery dissection.jpeg

IntroductionDifferences in pathophysiology, clinical presentation, and natural course of ST-elevation myocardial infarction in female patients due to either spontaneous dissection (SCAD-STEMI) or atherothrombotic occlusion (type 1 STEMI) have been discussed. Current knowledge on differences in left ventricular myocardial function and infarct size is limited. The aim of this study was to assess baseline clinical characteristics, imaging findings, and therapeutic approach and to compare differences in echocardiographic findings at baseline and 3-month follow-up in patients with SCAD-STEMI and type 1 STEMI.MethodsThis was a prospective multicenter study of 32 female patients (18–55 years of age) presenting with either SCAD-STEMI due to left anterior descending coronary artery (LAD) dissection or type 1 STEMI due to atherothrombotic LAD occlusion.ResultsThe two groups were similar in age, risk factors, comorbidities, and complications. SCAD-STEMI patients more often had Thrombolysis in Myocardial Infarction 3 flow, while type 1 STEMI patients were more often treated with percutaneous coronary intervention and dual antiplatelet therapy. Baseline mean left ventricular (LV) ejection fraction (LVEF) was similar in the two groups (48.0% vs. 48.6%, p = 0.881), but there was a significant difference at the 3-month follow-up, driven by an improvement in LVEF in SCAD-STEMI compared to type 1 STEMI patients (Δ LVEF 10.1 ± 5.3% vs. 1.8 ± 5.1%, p = 0.002). LV global longitudinal strain was slightly improved in both groups at follow-up; however, the improvement was not significantly different between groups (−4.6 ± 2.9% vs. −2.0 ± 2.8%, p = 0.055).ConclusionsThe results suggest that female patients with SCAD-STEMI are more likely to experience improvement in LV systolic function than type 1 STEMI patients.</p

Image3_Differences in left ventricular myocardial function and infarct size in female patients with ST elevation myocardial infarction and spontaneous coronary artery dissection.jpeg

IntroductionDifferences in pathophysiology, clinical presentation, and natural course of ST-elevation myocardial infarction in female patients due to either spontaneous dissection (SCAD-STEMI) or atherothrombotic occlusion (type 1 STEMI) have been discussed. Current knowledge on differences in left ventricular myocardial function and infarct size is limited. The aim of this study was to assess baseline clinical characteristics, imaging findings, and therapeutic approach and to compare differences in echocardiographic findings at baseline and 3-month follow-up in patients with SCAD-STEMI and type 1 STEMI.MethodsThis was a prospective multicenter study of 32 female patients (18–55 years of age) presenting with either SCAD-STEMI due to left anterior descending coronary artery (LAD) dissection or type 1 STEMI due to atherothrombotic LAD occlusion.ResultsThe two groups were similar in age, risk factors, comorbidities, and complications. SCAD-STEMI patients more often had Thrombolysis in Myocardial Infarction 3 flow, while type 1 STEMI patients were more often treated with percutaneous coronary intervention and dual antiplatelet therapy. Baseline mean left ventricular (LV) ejection fraction (LVEF) was similar in the two groups (48.0% vs. 48.6%, p = 0.881), but there was a significant difference at the 3-month follow-up, driven by an improvement in LVEF in SCAD-STEMI compared to type 1 STEMI patients (Δ LVEF 10.1 ± 5.3% vs. 1.8 ± 5.1%, p = 0.002). LV global longitudinal strain was slightly improved in both groups at follow-up; however, the improvement was not significantly different between groups (−4.6 ± 2.9% vs. −2.0 ± 2.8%, p = 0.055).ConclusionsThe results suggest that female patients with SCAD-STEMI are more likely to experience improvement in LV systolic function than type 1 STEMI patients.</p

Image2_Differences in left ventricular myocardial function and infarct size in female patients with ST elevation myocardial infarction and spontaneous coronary artery dissection.jpeg

IntroductionDifferences in pathophysiology, clinical presentation, and natural course of ST-elevation myocardial infarction in female patients due to either spontaneous dissection (SCAD-STEMI) or atherothrombotic occlusion (type 1 STEMI) have been discussed. Current knowledge on differences in left ventricular myocardial function and infarct size is limited. The aim of this study was to assess baseline clinical characteristics, imaging findings, and therapeutic approach and to compare differences in echocardiographic findings at baseline and 3-month follow-up in patients with SCAD-STEMI and type 1 STEMI.MethodsThis was a prospective multicenter study of 32 female patients (18–55 years of age) presenting with either SCAD-STEMI due to left anterior descending coronary artery (LAD) dissection or type 1 STEMI due to atherothrombotic LAD occlusion.ResultsThe two groups were similar in age, risk factors, comorbidities, and complications. SCAD-STEMI patients more often had Thrombolysis in Myocardial Infarction 3 flow, while type 1 STEMI patients were more often treated with percutaneous coronary intervention and dual antiplatelet therapy. Baseline mean left ventricular (LV) ejection fraction (LVEF) was similar in the two groups (48.0% vs. 48.6%, p = 0.881), but there was a significant difference at the 3-month follow-up, driven by an improvement in LVEF in SCAD-STEMI compared to type 1 STEMI patients (Δ LVEF 10.1 ± 5.3% vs. 1.8 ± 5.1%, p = 0.002). LV global longitudinal strain was slightly improved in both groups at follow-up; however, the improvement was not significantly different between groups (−4.6 ± 2.9% vs. −2.0 ± 2.8%, p = 0.055).ConclusionsThe results suggest that female patients with SCAD-STEMI are more likely to experience improvement in LV systolic function than type 1 STEMI patients.</p